| アブストラクト | OBJECTIVES: Due to the multisystemic nature of sickle cell disease (SCD), complications can occur together and thus discerning costs associated with individual complications requires a methodology that can estimate the costs of a given complication while accounting for the presence of other complications. In this study, we aimed to estimate period-based incremental costs associated with specific chronic complications in patients with SCD in England while accounting for multimorbidity. DESIGN/SETTING: All-cause primary and secondary care healthcare resource utilisation (HCRU) was obtained for a retrospective cohort of patients with SCD using Clinical Practice Research Datalink (CPRD) Aurum linked to Hospital Episode Statistics (HES) datasets. Annualised HCRU and costs were calculated, dividing patient-level events by patient-level time (in years) to obtain per person per year estimates. A series of generalised linear models were used with adjustment for demographic factors and proportion of follow-up time with each complication to estimate the costs associated with 10 chronic SCD-related complications of interest. For these costs, annual equivalent costs can be obtained by dividing by the median follow-up time of 4.74 years. PARTICIPANTS: Patients with a diagnosis of SCD, with or without complications, in CPRD or HES with at least 12 months follow-up. OUTCOME MEASURES: Period-based all-cause direct healthcare costs. RESULTS: Of the 1271 patients with SCD included in the study, 49.9% (n=634) had at least one complication and of these 41.3% (n=262) had two or more complications either at baseline or during follow-up. Patients with complications had higher all-cause healthcare costs compared with patients without complications (mean (SD) annualised cost pound16 058 ( pound21 488) vs pound4399 ( pound6635)). Patients with complications had four times the number of annualised inpatient admissions (6.1 vs 1.5 admissions) and more than double the number of annualised bed days in hospital (8.3 vs 3.8 days) over a median 4.74 years of follow-up. Of the complications evaluated, end-stage renal disease had the highest estimated incremental cost of pound252 083 (95% CI pound214 478 to pound283 745) over 4.74 years; this is in addition to the pound18 547 period-based cost among patients with SCD without complications. Osteonecrosis was the most common complication with an estimated incremental cost of pound27 399 (95% CI pound6417 to pound43 319) over the same period. CONCLUSION: Estimating the cost of complications, while accounting for multimorbidity, is essential to determine the true direct cost of SCD. The modelling method presented in our study provides period-based estimates of cost and hospital admissions for individual complications in patients with SCD, accounting for multimorbidity. This approach can be used and extended to other diseases with multisystemic complications to estimate the direct HCRU and costs of individual complications. |
|---|
| ジャーナル名 | BMJ open |
|---|
| Pubmed追加日 | 2026/2/5 |
|---|
| 投稿者 | Barcelos, Giovanna Tedesco; Besser, Martin; Davidson, Jennifer A; Filonenko, Anna; Telfer, Paul; Joao Carvalho, Sara; Jiang, Lili; Wirz, Reto; Rice, Caoimhe T |
|---|
| 組織名 | Pfizer AG, Zurich, Switzerland giovanna.barcelos@pfizer.com.;Department of Haematology, Addenbrooke's Hospital, Cambridge, UK.;Specialty EMR Data Division, CorEvitas, Cheshire, UK.;Pfizer, Berlin, Germany.;Centre for Genomics and Child Health, Blizard Institute, Queen Mary University of;London, London, UK.;Pfizer Inc, New York City, New York, USA.;Pfizer AG, Zurich, Switzerland. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/41638745/ |
|---|
